PRLD: Prelude Therapeutics Incorporated 2021-11-08 09:00:00 Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
PRLD has retraced to fib 0.95 and is close to the IPO price. I am buying today. First target - 60. Second target - 90.
PRLD fell very close to the yearly low after creation of an ugly top. You can measure down from the highest peak in the top to the neckline, then use the magnet to project it downward from the neckline to get a guesstimate of how low the top will take price. Possibly a double bttom if the most recent bottom is in. Appears to be moving. No recommendation
It may pullback from this level before going up again. Not financial advice, do your own DD all the time.
IPO intraday trading strategy idea Prelude Therapeutics is a clinical-stage biopharma developing treatments for various cancers. The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long...